Conditions: Alzheimer's Disease
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 649
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the long-term safety and tolerability of Dimebon in patients with Alzheimer's disease.

Detailed description:
This study was terminated on May 7, 2010 as part of modification of the dimebon development plan following lack of demonstration of efficacy in the completed DIM14 (CONNECTION) Study. The study was not terminated due to any safety findings. Dimebon has been well -tolerated in clinical trials. Demonstration of efficacy for dimebon in Alzheimer's disease is pending completion of the ongoing DIM18 (CONCERT) Study.

Arms:
arm 1: 10 mg TID for Week 1, followed by 20 mg TID for remainder of study

Interventions: intervention 1: Dimebon
Intervention descriptions: intervention 1: Tablet for oral administration

Protocol document: